公开(公告)号：US20180353561A1

公开(公告)日：2018-12-13

申请号：US15573207

申请日：2016-05-13

Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Inventor： Sei-Ryang OH ,  Kyung Seop AHN ,  Su Ui LEE ,  Hyung Won RYU ,  Doo-Young KIM ,  Hyeong Kyu LEE ,  Ok-Kyoung KWON ,  Jung Hee KIM ,  Hyun-Jun LEE ,  In-Sik SHIN

IPC: A61K36/575 ,  A61K31/34 ,  A61K31/357 ,  A61P35/00 ,  A61P9/00

CPC classification number: A61K36/575 ,  A61K9/0019 ,  A61K9/0095 ,  A61K31/34 ,  A61K31/357 ,  A61K31/36 ,  A61K47/38 ,  A61P9/00 ,  A61P11/00 ,  A61P35/00

Abstract: A pharmaceutical composition includes any of an extract of Magnoliae flos, a fraction or an active fraction obtained by fractionation thereof with an organic solvent, and a compound separated therefrom as an active ingredient. The extract of Magnoliae flos, the fraction or the active fraction obtained by fractionation thereof with an organic solvent, or the compound separated therefrom inhibits the expression of MUC5AC induced by TNF-α and the promoter activity in human lung cancer mucosal cells (H292), reduces the number of inflammatory cells in the bronchoalveolar lavage fluid of the chronic obstructive pulmonary disease mouse model, inhibits the production of reactive oxygen species, and reduces the cytokines; and therefore are effective in preventing or treating chronic obstructive pulmonary disease.

公开(公告)号：US20220151979A1

公开(公告)日：2022-05-19

申请号：US17439577

申请日：2020-02-26

Applicant: SEOUL NATIONAL UNIVERSITY HOSPITAL ,  KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Inventor： Hyo-Soo KIM ,  Hyun-Duk JANG ,  Kyung Seop AHN ,  Sei-Ryang OH ,  Ji Won PARK ,  Ok-Kyoung KWON ,  Hyung Won RYU

IPC: A61K31/352 ,  A61K31/40 ,  A61K31/505 ,  A61K31/47 ,  A61K31/22 ,  A61K31/366 ,  A61K31/405 ,  A61P9/10

Abstract: The present invention relates to a composition for prevention or treatment of cardiovascular and metabolic diseases, containing noranhydroicaritin or a pharmaceutically acceptable salt thereof, and the noranhydroicaritin or pharmaceutically acceptable salt thereof of the present invention is not toxic to cells, is thus safe, inhibits the production of PCSK9, promotes the production of LDLR, and is highly utilizable as a composition for prevention or treatment of cardiovascular and metabolic diseases. The noranhydroicaritin of the present invention can be used in a food composition for prevention or improvement of cardiovascular and metabolic diseases, a functional food composition for prevention or improvement of cardiovascular and metabolic diseases, and a method of preventing or treating cardiovascular and metabolic diseases, which includes administering a composition containing noranhydroicaritin as an active ingredient.

公开(公告)号：US20160332980A1

公开(公告)日：2016-11-17

申请号：US15221025

申请日：2016-07-27

Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY ,  DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Inventor： Kyeong LEE ,  Sei-Ryang OH ,  Kyung Seop AHN ,  Ok-Kyoung KWON ,  Doo-Young KIM ,  Hyung Won RYU ,  Jung Hee KIM ,  Xuezhen XU

IPC: C07D307/78 ,  C07C41/01 ,  C07C43/23

CPC classification number: C07D307/78 ,  A61K31/05 ,  A61K31/343 ,  C07C41/01 ,  C07C43/23 ,  C07D307/79 ,  C07D307/80 ,  C07D307/81

Abstract: The present invention relates to a novel 2-phenylbenzofuran derivative or a pharmaceutically acceptable salt thereof, a production method for the same, and a pharmaceutical composition for preventing or treating an inflammatory disease comprising the same as an active ingredient, and the novel 2-phenylbenzofuran derivative or the pharmaceutically acceptable salt thereof according to the present invention is outstandingly effective in suppressing NO, IL-6, and TNF-alpha induced by macrophages, and therefore can advantageously be used in a pharmaceutical composition for preventing or treating an inflammatory disease.

Abstract translation: 本发明涉及一种新的2-苯基苯并呋喃衍生物或其药学上可接受的盐，其制备方法和用于预防或治疗包含其的活性成分的炎性疾病的药物组合物，并且该新的2-苯基苯并呋喃 衍生物或其药学上可接受的盐在抑制由巨噬细胞诱导的NO，IL-6和TNF-α中显着有效，因此可有利地用于预防或治疗炎性疾病的药物组合物中。

公开(公告)号：US20160199339A1

公开(公告)日：2016-07-14

申请号：US14912920

申请日：2014-08-19

Applicant: ENZYCHEM LIFESCIENCES CORPORATION ,  KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Inventor： Sei-Ryang OH ,  Kyung Seop AHN ,  Su Ui LEE ,  In Sik SHIN ,  Na-Rae SHIN ,  Tae-Suk LEE ,  JongKoo KANG ,  Young-Sik JUNG ,  Yong-Hae HAN ,  Ki Young SOHN

IPC: A61K31/231

CPC classification number: A61K31/231 ,  A23K20/00 ,  A23L33/40 ,  A23V2002/00 ,  A61K35/32

Abstract: The present invention relates to a pharmaceutical composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing or treating asthma, and a functional health food composition for preventing or treating asthma. The monoacetyldiacylglycerol compound of the present invention inhibits the expression of IL-4 in EL-4 cells, which are mouse T cell lymphoma cells, reduces hypersensitivity of airway in an asthma-induced animal model, and inhibits the infiltration of inflammatory cells into the bronchial tube. In addition, the compounds of the present invention inhibit the generation of IgE in the serum and bronchoalveolar lavage fluid, have an excellent effect of inhibiting the expression of Th2 cytokines (IL-4, IL-5, and IL-13) in the lung, thereby overcome side effects of the currently used therapeutic agents for asthma, have no toxicity, and exhibit a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating asthma.

Abstract translation: 本发明涉及一种含有单乙酰基二酰基甘油化合物作为预防或治疗哮喘的活性成分的药物组合物，以及用于预防或治疗哮喘的功能保健食品组合物。 本发明的单乙酰基二酰基甘油化合物抑制作为小鼠T细胞淋巴瘤细胞的EL-4细胞中IL-4的表达，降低哮喘诱发的动物模型中气道的超敏反应，并抑制炎症细胞浸润到支气管 管。 此外，本发明的化合物抑制血清和支气管肺泡灌洗液中IgE的产生，具有抑制肺中Th2细胞因子（IL-4，IL-5和IL-13）表达的优异效果 从而克服目前使用的哮喘治疗剂的副作用，没有毒性，表现出优异的治疗效果，因此可用作预防，治疗和缓解哮喘的组合物。

公开(公告)号：US20240261356A1

公开(公告)日：2024-08-08

申请号：US18290222

申请日：2022-05-11

Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Inventor： Su Ui LEE ,  Mun-Ock KIM ,  Hyung Won RYU ,  Sei-Ryang OH ,  Doo-Young KIM ,  Jae-Won LEE

IPC: A61K36/254 ,  A61K31/191 ,  A61K31/365 ,  A61K36/38 ,  A61P1/16

CPC classification number: A61K36/254 ,  A61K31/191 ,  A61K31/365 ,  A61K36/38 ,  A61P1/16 ,  A61K2236/39

Abstract: The present invention relates to a composition containing extracts from Garcinia cambogia and Acanthopanax for prevention or treatment of liver diseases and, more specifically, to a composition for prevention or treatment of liver disease, the composition containing, as active ingredients, (i) a Garcinia cambogia extract, hydroxycitric acid (HCA), or a derivative of hydroxycitric acid; and (ii) an Acanthopanax extract, Chiisanogenin, or a derivative of Chiisanogenin.

公开(公告)号：US20170042854A1

公开(公告)日：2017-02-16

申请号：US14912765

申请日：2014-08-19

Applicant: ENZYCHEM LIFESCIENCES CORPORATION ,  KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Inventor： Sei-Ryang OH ,  Kyung Seop AHN ,  Su Ui LEE ,  In Sik SHIN ,  Ok-Kyoung KWON ,  Seung Hyung KIM ,  Chan Mi CHUN ,  Tae-Suk LEE ,  Yong-Hae HAN ,  Ki Young SOHN ,  JongKoo KANG ,  Hye Kyung KIM

IPC: A61K31/231

CPC classification number: A61K31/231

Abstract: The present invention relates to a pharmaceutical composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing or treating chronic obstructive pulmonary diseases, and a functional health food composition for treating or preventing chronic obstructive pulmonary diseases. The monoacetyldiacylglycerol compound of the present invention inhibits the IL-4 expression in EL-4 cells and inhibits the infiltration of inflammatory cells into the bronchial tube in an animal model. In addition, the compounds of the present invention have an excellent effect of inhibiting the expression of CXCL-1, TNF-α, or MIP-2, thereby overcoming side effects of the currently used therapeutic agents for chronic obstructive pulmonary diseases, having no toxicity, and exhibiting a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating chronic obstructive pulmonary diseases.

Abstract translation: 本发明涉及含有单乙酰二酰基甘油化合物作为预防或治疗慢性阻塞性肺疾病的活性成分的药物组合物，以及用于治疗或预防慢性阻塞性肺疾病的功能保健食品组合物。 本发明的单乙酰基二酰基甘油化合物抑制EL-4细胞中的IL-4表达，并且在动物模型中抑制炎性细胞浸润到支气管中。 此外，本发明的化合物具有抑制CXCL-1，TNF-α或MIP-2的表达的优异效果，从而克服了目前使用的治疗剂对于无毒性的慢性阻塞性肺疾病的副作用 并且具有优异的治疗效果，因此可用作预防，治疗和缓解慢性阻塞性肺疾病的组合物。

公开(公告)号：US20160193174A1

公开(公告)日：2016-07-07

申请号：US14915799

申请日：2014-09-03

Applicant: ENZYCHEM LIFESCIENCES CORPORATION ,  KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Inventor： Jae Wha KIM ,  Sei-Ryang OH ,  Kyung Seop AHN ,  Ho Bum KANG ,  Jae Mine YOO ,  Tae-Suk LEE ,  JongKoo KANG ,  Hye Kyung KIM ,  Jin Soo YOOK ,  Yong-Hae HAN ,  Ki Young SOHN

IPC: A61K31/231 ,  A61Q19/00 ,  A61K9/00 ,  A61K8/37

CPC classification number: A61K31/231 ,  A23L33/10 ,  A23V2002/00 ,  A61K8/37 ,  A61K9/0014 ,  A61K9/08 ,  A61K47/44 ,  A61K2800/10 ,  A61Q19/00

Abstract: The present invention relates to a pharmaceutical composition, functional health food composition, quasi-drug composition, and cosmetic composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing, treating or improving atopic dermatitis. The monoacetyldiacylglycerol compound of the present invention has an excellent effect of suppression of IL-4 and IgE secretion, thereby overcoming side effects of an atopic dermatitis treatment agent currently in use, having no toxicity, and exhibiting an excellent treatment effect, and thus can be useful as a composition for preventing, treating, and ameliorating atopic dermatitis.

Abstract translation: 本发明涉及含有单乙酰二酰基甘油化合物作为预防，治疗或改善特应性皮炎的活性成分的药物组合物，功能保健食品组合物，准药物组合物和化妆品组合物。 本发明的单乙酰基二酰基甘油化合物具有抑制IL-4和IgE分泌的优异效果，从而克服目前使用的特应性皮炎治疗剂的副作用，无毒性，并具有优异的治疗效果，因此可以 可用作预防，治疗和改善特应性皮炎的组合物。

公开(公告)号：US20240254155A1

公开(公告)日：2024-08-01

申请号：US18564361

申请日：2022-05-04

Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Inventor： Hyung Won RYU ,  Su Ui LEE ,  Sei-Ryang OH ,  Jae-Won LEE ,  Doo-Young KIM ,  Hyun-Jae JANG ,  Mun-Ock KIM ,  Seong Hun JEONG

IPC: C07H15/256 ,  A61K31/704 ,  A61K36/21 ,  A61P11/06 ,  A61P29/00 ,  C07H1/08

CPC classification number: C07H15/256 ,  A61K31/704 ,  A61K36/21 ,  A61P11/06 ,  A61P29/00 ,  C07H1/08 ,  A61K2236/33 ,  A61K2236/55

Abstract: The present invention relates to a novel compound isolated from spinach, and a composition comprising same for preventing or treating inflammatory diseases, and, more particularly, to a novel medicagenic acid glycoside compound isolated from spinach, a preparation method therefor, and a composition comprising same for preventing or treating inflammatory diseases.

公开(公告)号：US20230144344A1

公开(公告)日：2023-05-11

申请号：US17910894

申请日：2021-03-11

Applicant: SEOUL NATIONAL UNIVERSITY HOSPITAL ,  KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Inventor： Hyo-soo KIM ,  Hyun-duk JANG ,  Kyung Seop AHN ,  Sei-Ryang OH ,  Ok-Kyoung KWON ,  Hyung Won RYU ,  Hang JIN ,  Sangho CHOI ,  Sang Woo LEE ,  Jin Hyub PAIK ,  Soo Yong KIM ,  Changyoung LEE ,  Yong In KIM ,  Hyewon KIM ,  Mijin PARK

IPC: A61K36/185 ,  A61K31/7048 ,  A61P9/00

CPC classification number: A61K36/185 ,  A61K31/7048 ,  A61P9/00 ,  A61K2236/333 ,  A61K2236/35

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating cardiovascular and metabolic diseases, comprising an Elaeocarpus petiolatus extract, a fraction thereof, or a compound isolated therefrom, as an active ingredient; a food composition for preventing or improving cardiovascular and metabolic diseases; and a method for preventing or treating cardiovascular and metabolic diseases using the same.
The composition comprising an Elaeocarpus petiolatus extract, a fraction thereof, or a compound isolated therefrom inhibits the binding of Resistin-CAP1 to inhibit the production of tumor necrosis factor, and thereby has an activity of inhibiting inflammation of the cardiovascular system, and thus can be effectively used as a preventive or therapeutic measure for cardiovascular and metabolic diseases.

公开(公告)号：US20170174645A1

公开(公告)日：2017-06-22

申请号：US15449465

申请日：2017-03-03

Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY ,  DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Inventor： Kyeong LEE ,  Sei-Ryang OH ,  Kyung Seop AHN ,  Ok-Kyoung KWON ,  Doo-Young KIM ,  Hyung Won RYU ,  Jung Hee KIM ,  Xuezhen XU

IPC: C07D307/86 ,  A23L33/10

CPC classification number: C07D307/86 ,  A23L33/10 ,  A23V2002/00 ,  A61K31/05 ,  A61K31/343 ,  C07D307/78 ,  C07D307/79 ,  C07D307/80 ,  C07D307/81

Abstract: The present invention relates to a novel 2-phenylbenzofuran derivative or a pharmaceutically acceptable salt thereof, a production method for the same, and a pharmaceutical composition for preventing or treating an inflammatory disease comprising the same as an active ingredient, and the novel 2-phenylbenzofuran derivative or the pharmaceutically acceptable salt thereof according to the present invention is outstandingly effective in suppressing NO, IL-6, and TNF-alpha induced by macrophages, and therefore can advantageously be used in a pharmaceutical composition for preventing or treating an inflammatory disease.